Tag: Royalty Pharma
PTC Therapeutics collaborates with Royalty Pharma in $1.5bn Evrysdi royalty agreement
PTC Therapeutics, Inc. (NASDAQ: PTCT) has forged an agreement with Royalty Pharma plc., monetizing up to a staggering $1.5 billion from the Evrysdi royalty stream. ... Read More
Ipsen to acquire American biopharma company Epizyme for $247m
French pharma company Ipsen has agreed to acquire Epizyme, a Massachusetts-based commercial-stage biopharma company for an initial consideration of $247 million. Epizyme, which is listed ... Read More